Indole, indazole and benzisoxazole compounds

• US 5,703,070 A
• Filed: 06/06/1996
• Issued: 12/30/1997
• Est. Priority Date: 06/07/1995
• Status: Expired due to Fees

• Current Assignee: Les Laboratoires Servier (Servier Sas)
• Original Assignee: Adir SA
• Inventors: Millan, Mark, Muller, Olivier, Lavielle, Gilbert, Audinot, Valerie
• Primary Examiner(s): Shah, Mukund J.
• Assistant Examiner(s): Rao, Deepak R.
• Application Number:
  US08/663,464
• Time in Patent Office: 572 Days
• Field of Search: 548/207, 548/241, 548/361.1, 548/362.5, 548/468, 540/602, 540/603, 514/212, 514/373, 514/379, 514/406, 514/419
• US Class Current: 514/217.08
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 403/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 413/06 linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Compound of formula (I): ##STR1## in which: R₁ represents hydrogen, halogen, alkyl, alkoxy, trihalomethyl or hydroxyl,

R₂ represents hydrogen, alkyl or phenyl which is optionally substituted, ##STR2## or alternatively ##STR3## represents --O--N═, 1≦n≦6, ##STR4## represents any one of the groups defined in the description, its isomers and its addition salts with a pharmaceutically acceptable acid or base, a medicinal products containing the same are useful in the treatment of schizophrenia.

Claims

1. A compound selected from the group having formula (I):

##STR16## in which;

R₁ represents hydrogen, halogen, linear or branched (C₁ -C₆)alkyl, linear or branched (C₁ -C₆)alkoxy, trihalomethyl, or hydroxyl,

R₂ represents hydrogen or linear or branched (C₁ -C₆)alkyl or a phenyl group which is unsubstituted or substituted by halogen, alkyl, alkoxy, hydroxyl, or trihalomethyl, ##STR17## or represents --O--N═

, n is 1, 2, 3, 4, 5, or 6 ##STR18## represents any one of the following groups;

##STR19## in which;

R represents hydrogen, halogen, linear or branched (C₁ -C₆)alkyl, linear or branched (C₁ -C₆)alkoxy, hydroxyl, or trihalomethyl,

Z represents oxygen, sulfur, or --NH--,

its isomers and its addition salts with a pharmaceutically-acceptable acid or base.

2. A compound of claim 1, wherein ##STR20##

3. A compound of claim 1, wherein n is equal to 2.

4. A compound of claim 1, wherein n is equal to 3.

5. A compound of claim 1, wherein ##STR21##

6. A compound of claim 1, wherein ##STR22##

7. A compound of claim 1, wherein ##STR23##

8. A method for treating a living animal body afflicted with a schizophrenic condition comprising the step of administering to the living animal body an amount of a compound of claim 1 which is effective for alleviation of said condition.

9. A pharmaceutical composition useful in treating schizophrenia comprising as active principle an effective amount of a compound of claim 1, together with one or more pharmaceutically-acceptable excipients or vehicles.